

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Abbisko Cayman Limited**  
**和譽開曼有限責任公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2256)**

**VOLUNTARY ANNOUNCEMENT**  
**FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF**  
**PIMICOTINIB (ABSK021) IN THE TREATMENT OF ADVANCED**  
**PANCREATIC CANCER IN CHINA**

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced the first patient has been dosed in the study titled “A Multicenter, Open-Label Phase II Study to Evaluate the Efficacy and Safety of ABSK021 in Combination with Chemotherapy with or without Toripalimab in Patients with Advanced Pancreatic Cancer (Protocol No.: ABSK021 – 202)” at the leading site Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

This is a voluntary announcement made by the Company. The Group cannot guarantee that pimicotinib (ABSK021) will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Abbisko Cayman Limited**  
**Dr. Xu Yao-Chang**  
*Chairman*

Shanghai, November 28, 2023

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.*

## **Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib (ABSK021) in China**

November 28, 2023, Abbisko Therapeutics announced the first patient has been dosed in the study titled “A Multicenter, Open-Label Phase II Study to Evaluate the Efficacy and Safety of ABSK021 in Combination with Chemotherapy with or without Toripalimab in Patients with Advanced Pancreatic Cancer (Protocol No.: ABSK021 – 202)” at the leading site Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

Currently, pancreatic cancer is the 7th leading cause of cancer-related deaths worldwide and is the malignant tumor with the mortality closest to incidences. The diagnosis of pancreatic cancer is typically challenging, as there are no specific available screening tests and early symptoms are often subtle and atypical. As a result, a significant number of patients are diagnosed at an advanced stage, lacking of the opportunity for radical surgery. Surgical resection is currently the only chance for curing pancreatic cancer. However, more than 80% of pancreatic cancer patients lose this opportunity due to diagnosis at the advanced stage. New breakthroughs in the treatment of pancreatic cancer are urgently needed, and the development of novel therapeutic drugs and approaches represent the hope for overcoming this disease in the future.

Pimicotinib is a novel, orally available, highly selective, and highly potent small molecule inhibitor of CSF-1R independently discovered and developed by Abbisko Therapeutics. A number of studies have shown that blocking the CSF1/CSF1R signaling pathway could modulate and change macrophage functions, which helps to remodel the tumor immunosuppressive microenvironment. Abbisko Therapeutics obtained the clinical trial approval for pimicotinib from the NMPA on 12 June, 2023 for the treatment of advanced pancreatic cancer. Besides of leading site, other sites are scheduled to be initiated successively and 16 investigation sites are planned. Patient recruitment has begun.

### **About Abbisko Therapeutics**

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (stock code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to meet unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 15 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.

Please visit [www.abbisko.com](http://www.abbisko.com) for more information.

### **Forward-Looking Statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements were made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements were made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, the intentions of our Directors or our Company were made as of the date of this article. Any of these intentions may alter in light of future development.